<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18065" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Azathioprine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mohammadi</surname>
            <given-names>Oranus</given-names>
          </name>
          <aff>Aventura Hospital and Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kassim</surname>
            <given-names>Thamer A.</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Oranus Mohammadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thamer Kassim declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18065.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Azathioprine (AZA) is a medication used in the management and treatment of active rheumatoid arthritis (RA) and the prevention of kidney transplant rejection. This activity reviews the indications, action, and contraindications for azathioprine as a valuable agent in treating RA and other disorders when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the treatment of patients with RA and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of azathioprine.</p></list-item><list-item><p>Identify the most common adverse events associated with azathioprine therapy.</p></list-item><list-item><p>Explain the importance of monitoring for patients on azathioprine therapy.</p></list-item><list-item><p>Outline the importance of collaboration and coordination among the interprofessional team to enhance patient care when monitoring azathioprine to improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18065&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18065">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18065.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Azathioprine (AZA)&#x000a0;is approved by the Food and Drug Administration (FDA)&#x000a0;for the symptomatic&#x000a0;treatment of active rheumatoid arthritis. It also has approval as adjunctive therapy for the prevention of kidney transplant rejection.<xref ref-type="bibr" rid="article-18065.r1">[1]</xref><xref ref-type="bibr" rid="article-18065.r2">[2]</xref></p>
        <p>AZA&#x000a0;used off-label for the treatment of inflammatory bowel disease,<xref ref-type="bibr" rid="article-18065.r3">[3]</xref> Churg-Strauss syndrome, autoimmune hepatitis (for&#x000a0;maintenance treatment along with steroids),<xref ref-type="bibr" rid="article-18065.r4">[4]</xref><xref ref-type="bibr" rid="article-18065.r5">[5]</xref> chronic ITP (second-line agent),<xref ref-type="bibr" rid="article-18065.r6">[6]</xref> lupus nephritis,<xref ref-type="bibr" rid="article-18065.r1">[1]</xref> connective tissue disease-associated ILD,<xref ref-type="bibr" rid="article-18065.r7">[7]</xref> multiple sclerosis, severe myasthenia gravis, recurrent pericarditis,<xref ref-type="bibr" rid="article-18065.r8">[8]</xref> psoriasis, non-infectious uveitis,<xref ref-type="bibr" rid="article-18065.r9">[9]</xref> relapsing polychondritis,<xref ref-type="bibr" rid="article-18065.r10">[10]</xref> dermatomyositis/polymyositis, erythema multiforme, severe and refractory atopic dermatitis, chronic actinic dermatitis, pyoderma gangrenosum, Behcet disease, cutaneous vasculitis, pityriasis rubra pilaris, lichen planus, bullous pemphigoid, and pemphigus vulgaris.<xref ref-type="bibr" rid="article-18065.r2">[2]</xref><xref ref-type="bibr" rid="article-18065.r11">[11]</xref> Of note, AZA or 6-MP are treatment options for Crohn disease in children as a maintenance treatment.<xref ref-type="bibr" rid="article-18065.r12">[12]</xref></p>
      </sec>
      <sec id="article-18065.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Azathioprine is&#x000a0;a purine analog that converts to&#x000a0;its active metabolites,&#x000a0;mercaptopurine (6-MP) and thioguanine (6-TGN), by the action of hypoxanthine-guanine phosphoribosyltransferase (HPRT) and thiopurine methyltransferase (TPMT)&#x000a0;enzymes. It then&#x000a0;inhibits purine synthesis.<xref ref-type="bibr" rid="article-18065.r13">[13]</xref> Its metabolites&#x000a0;are incorporated into the replicating DNA and halt division.&#x000a0;AZA metabolites may also mediate most of its immunosuppressive and toxic effects.&#x000a0;AZA&#x000a0;is absorbed&#x000a0;rapidly through the GI system and does not penetrate the blood-brain barrier. It undergoes metabolism in the liver, and excretion is via the kidneys, which&#x000a0;increases its&#x000a0;toxicity in renal failure.<xref ref-type="bibr" rid="article-18065.r2">[2]</xref></p>
      </sec>
      <sec id="article-18065.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The starting dose&#x000a0;for AZA&#x000a0;is&#x000a0;2 to 2.5 mg/kg/day, except for patients with TPMT or NUDT15 gene mutation, in which the starting dose is lower than normal.<xref ref-type="bibr" rid="article-18065.r14">[14]</xref> Dose adjustments are necessary for hepatic and kidney disease.<xref ref-type="bibr" rid="article-18065.r11">[11]</xref></p>
        <p>AZA tablets may be administered after meals to decrease adverse GI effects. Administration can be by IV push over 5 minutes, at a concentration not exceeding 5 mg/ml. It can be further diluted with NS or DW and administered by intermittent infusion over 30 to 60 minutes. However, it may also be infused over 5 minutes up to over 8 hours.</p>
      </sec>
      <sec id="article-18065.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Complications occur in 15 to 28% of patients.<xref ref-type="bibr" rid="article-18065.r2">[2]</xref></p>
        <p>
<bold>Frequent Side Effects</bold>
<xref ref-type="bibr" rid="article-18065.r15">[15]</xref>
<xref ref-type="bibr" rid="article-18065.r16">[16]</xref>
<xref ref-type="bibr" rid="article-18065.r13">[13]</xref>
<xref ref-type="bibr" rid="article-18065.r4">[4]</xref>
<xref ref-type="bibr" rid="article-18065.r17">[17]</xref>
<xref ref-type="bibr" rid="article-18065.r18">[18]</xref>
<xref ref-type="bibr" rid="article-18065.r19">[19]</xref>
<xref ref-type="bibr" rid="article-18065.r20">[20]</xref>
<xref ref-type="bibr" rid="article-18065.r21">[21]</xref>
<xref ref-type="bibr" rid="article-18065.r22">[22]</xref>
<xref ref-type="bibr" rid="article-18065.r23">[23]</xref>
<xref ref-type="bibr" rid="article-18065.r24">[24]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea; is the most frequent side effect
<list list-type="bullet"><list-item><p>Dose-dependent.</p></list-item><list-item><p>Early-onset nausea usually resolves without dose alteration</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Fever</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Arthralgias/myalgia</p>
          </list-item>
          <list-item>
            <p>Bone marrow suppression causing pancytopenia, thrombocytopenia, leukopenia - there are reports of dose-dependent, life-threatening cases.
<list list-type="bullet"><list-item><p>This complication correlates with the 6-TGN level</p></list-item><list-item><p>There is a higher risk of myelosuppression in patients who take allopurinol or ACEI and in renal insufficiency</p></list-item><list-item><p>An increase in the mean corpuscular volume of the red blood cells is also an expected side effect</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Rash</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity: Hepatic injury correlates with a 6-MMP level of more than 5700 pmol/8 x 10^8 RBC.</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity categorizes into two groups.
<list list-type="bullet"><list-item><p>Acute idiosyncratic liver injury happens in the early course and resolves with stopping the medication.&#x000a0;&#x000a0;</p></list-item><list-item><p>Nodular regenerative hyperplasia occurs in IBD and organ transplant patients several years after therapy.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Infections (7.4%): Concomitant use of AZA and steroids will increase the risk of PCP in leukopenic patients.</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity: symptoms including fever, chills, arthralgia/myalgia, liver abnormalities, erythema nodosum</p>
          </list-item>
          <list-item>
            <p>Kidney damage</p>
          </list-item>
        </list>
        <p>
<bold>Rare Side Effects</bold>
<xref ref-type="bibr" rid="article-18065.r25">[25]</xref>
<xref ref-type="bibr" rid="article-18065.r26">[26]</xref>
<xref ref-type="bibr" rid="article-18065.r27">[27]</xref>
<xref ref-type="bibr" rid="article-18065.r21">[21]</xref>
<xref ref-type="bibr" rid="article-18065.r28">[28]</xref>
<xref ref-type="bibr" rid="article-18065.r15">[15]</xref>
<xref ref-type="bibr" rid="article-18065.r11">[11]</xref>
<xref ref-type="bibr" rid="article-18065.r24">[24]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Carcinogenesis: cutaneous hyperkeratosis and nonmelanoma skin cancer (SCC)&#x000a0;in myasthenia gravis (most likely due to increased risk of photosensitivity), solid-organ transplant&#x000a0;and IBD patients/ lymphoma in transplant and IBD patients</p>
          </list-item>
          <list-item>
            <p>Pancreatitis (3.3%): more in females with&#x000a0;Crohn disease
<list list-type="bullet"><list-item><p>Dose-dependent</p></list-item><list-item><p>Usually happens in the first six weeks</p></list-item><list-item><p>In the case of pancreatitis, discontinue AZA</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Alopecia including telogen effluvium, anagen effluvium, and plica neuropathica</p>
          </list-item>
          <list-item>
            <p>Macrocytic anemia</p>
          </list-item>
          <list-item>
            <p>Sweet syndrome (acute febrile neutrophilic dermatosis)</p>
          </list-item>
          <list-item>
            <p>Pneumonitis: in IBD and renal transplant patients</p>
          </list-item>
          <list-item>
            <p>Upper airway edema</p>
          </list-item>
          <list-item>
            <p>Tremor: in transplant and Crohn patient: dose-dependent</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18065.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Contraindications</bold>
<xref ref-type="bibr" rid="article-18065.r29">[29]</xref>
<xref ref-type="bibr" rid="article-18065.r30">[30]</xref>
<xref ref-type="bibr" rid="article-18065.r31">[31]</xref>
<xref ref-type="bibr" rid="article-18065.r2">[2]</xref>
<xref ref-type="bibr" rid="article-18065.r32">[32]</xref>
</p>
        <list list-type="order">
          <list-item>
            <p>Hypersensitivity</p>
          </list-item>
          <list-item>
            <p>Pregnancy or plan for pregnancy: Contraception recommended.&#x000a0;AZA can increase the risk of spontaneous miscarriage, low birth weight, and preterm delivery. Although data in&#x000a0;systemic lupus erythematosus (SLE)&#x000a0;and renal transplant patients showed safety in pregnancy. In&#x000a0;some specific conditions like SLE and antiphospholipid antibody syndrome, the benefits of taking immunosuppressive medications are more than harms&#x000a0;in keeping the mother safe.</p>
          </list-item>
          <list-item>
            <p>Breastfeeding as 6-MP was present in breast-milk of women who take&#x000a0;azathioprine</p>
          </list-item>
          <list-item>
            <p>Unknown TPMT status or deficient TPMT activity due to the high risk of myelosuppression&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Known malignancy</p>
          </list-item>
          <list-item>
            <p>Clinically active infection</p>
          </list-item>
        </list>
        <p>
<bold>Relative Contraindications</bold>
<xref ref-type="bibr" rid="article-18065.r32">[32]</xref>
</p>
        <list list-type="order">
          <list-item>
            <p>Allopurinol intake concomitantly with AZA due to severe myelosuppression&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cyclophosphamide or chlorambucil treatment in the past</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18065.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <list list-type="bullet">
          <list-item>
            <p>It usually requires 6 to 8 weeks&#x000a0;for&#x000a0;AZA to&#x000a0;work. The recommendation is to consider stopping&#x000a0;the medication&#x000a0;if there is no improvement&#x000a0;in 3 months.<xref ref-type="bibr" rid="article-18065.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Checking TPMT activity is&#x000a0;suggested before starting the medication. Misclassification of TMPT phenotype can occur&#x000a0;by prior blood transfusion.<xref ref-type="bibr" rid="article-18065.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Test the patient for&#x000a0;hepatitis B and C and PPD. A pregnancy test before treatment initiation is also a recommendation.<xref ref-type="bibr" rid="article-18065.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Complete blood count (CBC)&#x000a0;and&#x000a0;liver function test (LFT)&#x000a0;monitoring weekly are recommended initially&#x000a0;for the first&#x000a0;4 to 8 weeks. CBC and LFT should get checked every three months for the rest of the treatment&#x000a0;once the maintenance dose is achieved. However, it is advisable to check CBC and LFT more frequently in patients with kidney or renal diseases or elderly patients on high dosages of AZA or low TPMT activity. If labs show leukopenia (WBC less than 3 x 10^9/L), thrombocytopenia (platelet less than 120 x 10^9/L), or transaminitis (liver biochemistry more than half of the normal upper limit), the medication should be stopped.<xref ref-type="bibr" rid="article-18065.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>If patients have abdominal pain or severe nausea/vomiting, serum amylase requires checking to rule out pancreatitis. Lymph node and skin examination should be biannual.<xref ref-type="bibr" rid="article-18065.r32">[32]</xref> If a generalized wart occurs, the AZA dose should be reduced or switched to another agent.</p>
          </list-item>
          <list-item>
            <p>Some&#x000a0;studies suggested monitoring the level of AZA metabolites (e.g., 6-TGN and 6-MP) to avoid specific complications.<xref ref-type="bibr" rid="article-18065.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18065.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity symptoms include&#x000a0;gastrointestinal symptoms, bradycardia, hepatotoxicity, myelosuppression.<xref ref-type="bibr" rid="article-18065.r33">[33]</xref> Acute toxicity usually happens when more than 1.5 times of daily dose is taken by the patient.&#x000a0;</p>
        <p>In the acute setting, activated charcoal may help with decreasing the symptoms within&#x000a0;two hours of ingestion.<xref ref-type="bibr" rid="article-18065.r34">[34]</xref> No specific antidote is known for AZA. In severe cases of toxicity, dialysis is permissible as AZA is dialysable.</p>
        <p>In cases of hepatic sinusoidal obstruction syndrome, it must discontinue permanently. If severely leukopenic, thrombocytopenic, or infected, treatment should stop.&#x000a0;</p>
      </sec>
      <sec id="article-18065.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Azathioprine is an immunomodulator associated with several serious adverse effects.&#x000a0;Susceptibility to its toxicity&#x000a0;varies&#x000a0;with age, genetic differences, and&#x000a0;medication dosage.&#x000a0;Its adverse effects are a limiting factor in the patient's compliance. Therefore regular follow-up&#x000a0;and frequent&#x000a0;laboratory workups are crucial to avoiding its complications. Clinicians and pharmacists should be aware of potential adverse effects of AZA, even in asymptomatic patients. Pharmacists should verify dosing is appropriate to the condition treated and report any discrepancies to the rest of the healthcare team. Nursing will often function at the "front lines" in seeing the patients and are often the first to know about adverse events, which they can report to the team. Nursing will also be in charge of administration, so they should verify dosing to ensure optimal therapeutic results with minimal adverse effects.</p>
        <p>In summary, azathioprine therapy requires an interprofessional team approach, including clinicians, specialists, mid-level practitioners, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level 5]</p>
      </sec>
      <sec id="article-18065.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18065&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18065">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18065/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18065">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18065.s11">
        <title>References</title>
        <ref id="article-18065.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ladri&#x000e8;re</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Current indications of azathioprine in nephrology].</article-title>
            <source>Nephrol Ther</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-12</page-range>
            <pub-id pub-id-type="pmid">23022291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anstey</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Wakelin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>NJ</given-names>
              </name>
              <collab>British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee</collab>
            </person-group>
            <article-title>Guidelines for prescribing azathioprine in dermatology.</article-title>
            <source>Br J Dermatol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>151</volume>
            <issue>6</issue>
            <fpage>1123</fpage>
            <page-range>1123-32</page-range>
            <pub-id pub-id-type="pmid">15606506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Herrlinger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Siegmund</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bokemeyer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stallmach</surname>
                <given-names>A</given-names>
              </name>
              <collab>Kompetenznetz Darmerkrankungen</collab>
            </person-group>
            <article-title>[Azathioprine in Crohn's disease therapy--guidance against the background of recent studies].</article-title>
            <source>Z Gastroenterol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>12</issue>
            <fpage>1423</fpage>
            <page-range>1423-30</page-range>
            <pub-id pub-id-type="pmid">25474282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheiko</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sundaram</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Capocelli</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>McCoy</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Outcomes in Pediatric Autoimmune Hepatitis and Significance of Azathioprine Metabolites.</article-title>
            <source>J Pediatr Gastroenterol Nutr</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-85</page-range>
            <pub-id pub-id-type="pmid">28272159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aljumah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Al Jarallah</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Albenmousa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Khathlan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Zanbagi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Quaiz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Judaibi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nabrawi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Al Hamoudi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Alghamdi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fallatah</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis.</article-title>
            <source>Saudi J Gastroenterol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>7 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-S20</page-range>
            <pub-id pub-id-type="pmid">30264737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>State of the art - how I manage immune thrombocytopenia.</article-title>
            <source>Br J Haematol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>177</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-54</page-range>
            <pub-id pub-id-type="pmid">28295192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oldham</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valenzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Adegunsoye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Montner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Noth</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vij</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Strek</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.</article-title>
            <source>Respir Med</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>121</volume>
            <fpage>117</fpage>
            <page-range>117-122</page-range>
            <pub-id pub-id-type="pmid">27888985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imazio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lazaros</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brucato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gaita</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Recurrent pericarditis: new and emerging therapeutic options.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-105</page-range>
            <pub-id pub-id-type="pmid">26259934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Touhami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diwo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>S&#x000e8;ve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Trad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bielefeld</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>S&#x000e8;ne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Br&#x000e9;zin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quartier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kon&#x000e9; Paut</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiquet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Errera</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Sellam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cacoub</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaplanski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kodjikian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bodaghi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saadoun</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Expert opinion on the use of biological therapy in non-infectious uveitis.</article-title>
            <source>Expert Opin Biol Ther</source>
            <year>2019</year>
            <month>May</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>477</fpage>
            <page-range>477-490</page-range>
            <pub-id pub-id-type="pmid">30888881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miyara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohen-Aubart</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haroche</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grenier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Amoura</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use.</article-title>
            <source>Best Pract Res Clin Rheumatol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>316</fpage>
            <page-range>316-333</page-range>
            <pub-id pub-id-type="pmid">27886803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meggitt</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Anstey</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Mohd Mustapa</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Wakelin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011.</article-title>
            <source>Br J Dermatol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>165</volume>
            <issue>4</issue>
            <fpage>711</fpage>
            <page-range>711-34</page-range>
            <pub-id pub-id-type="pmid">21950502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruemmele</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Veres</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kolho</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Escher</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Amil Dias</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barabino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Braegger</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Bronsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buderus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-de-Carpi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>De Ridder</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fagerberg</surname>
                <given-names>UL</given-names>
              </name>
              <name>
                <surname>Hugot</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kierkus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kolacek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koletzko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lionetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Miele</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Navas L&#x000f3;pez</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Paerregaard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Serban</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Shaoul</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Van Rheenen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Veereman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dignass</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eliakim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>D</given-names>
              </name>
              <collab>European Crohn's and Colitis Organisation</collab>
              <collab>European Society of Pediatric Gastroenterology, Hepatology and Nutrition</collab>
            </person-group>
            <article-title>Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.</article-title>
            <source>J Crohns Colitis</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>1179</fpage>
            <page-range>1179-207</page-range>
            <pub-id pub-id-type="pmid">24909831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Marinaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Life threatening myelotoxicity secondary to azathioprine in a patient with atopic eczema and normal thiopurine methyltransferase activity.</article-title>
            <source>BMJ</source>
            <year>2011</year>
            <month>Mar</month>
            <day>25</day>
            <volume>342</volume>
            <fpage>d1417</fpage>
            <pub-id pub-id-type="pmid">21441287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williet</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Roblin</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Trend towards dose reduction of azathioprine as monotherapy in inflammatory bowel disease patients: what about for combination therapy?</article-title>
            <source>Therap Adv Gastroenterol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-10</page-range>
            <pub-id pub-id-type="pmid">28286554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joshi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Plica Neuropathica (Plica polonica) Following Azathioprine-induced Pancytopenia.</article-title>
            <source>Int J Trichology</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>110</fpage>
            <page-range>110-2</page-range>
            <pub-id pub-id-type="pmid">21712900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steponaitiene</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kupcinskas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Survilaite</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Varkalaite</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jonaitis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kiudelis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Denapiene</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Valantinas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Skieceviciene</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kupcinskas</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects.</article-title>
            <source>Adv Med Sci</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>135</fpage>
            <page-range>135-40</page-range>
            <pub-id pub-id-type="pmid">26674571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <article-title>Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines.</article-title>
            <source>Arthritis Rheum</source>
            <year>1996</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>723</fpage>
            <page-range>723-31</page-range>
            <pub-id pub-id-type="pmid">8639168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melzer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ruck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fuhr</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hohlfeld</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Melms</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tackenberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schalke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schneider-Gold</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zimprich</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meuth</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Wiendl</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.</article-title>
            <source>J Neurol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>263</volume>
            <issue>8</issue>
            <fpage>1473</fpage>
            <page-range>1473-94</page-range>
            <pub-id pub-id-type="pmid">26886206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Broekman</surname>
                <given-names>MMTJ</given-names>
              </name>
              <name>
                <surname>Coenen</surname>
                <given-names>MJH</given-names>
              </name>
              <name>
                <surname>van Marrewijk</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wanten</surname>
                <given-names>GJA</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Verbeek</surname>
                <given-names>ALM</given-names>
              </name>
              <name>
                <surname>Klungel</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Hooymans</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Guchelaar</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Scheffer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Derijks</surname>
                <given-names>LJJ</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>TOPIC Recruitment Team</collab>
            </person-group>
            <article-title>More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.</article-title>
            <source>Inflamm Bowel Dis</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>10</issue>
            <fpage>1873</fpage>
            <page-range>1873-1881</page-range>
            <pub-id pub-id-type="pmid">28644183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinshilboum</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Sladek</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.</article-title>
            <source>Am J Hum Genet</source>
            <year>1980</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>651</fpage>
            <page-range>651-62</page-range>
            <pub-id pub-id-type="pmid">7191632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Vainer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rask-Madsen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>1699</fpage>
            <page-range>1699-708</page-range>
            <pub-id pub-id-type="pmid">11683683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saway</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Heck</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Bonner</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kirklin</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Azathioprine hypersensitivity. Case report and review of the literature.</article-title>
            <source>Am J Med</source>
            <year>1988</year>
            <month>May</month>
            <volume>84</volume>
            <issue>5</issue>
            <fpage>960</fpage>
            <page-range>960-4</page-range>
            <pub-id pub-id-type="pmid">3284343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-Olivares</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khedaoui</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Mor&#x000e1;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Borbujo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Azathioprine-Induced Hypersensitivity Reaction Presenting as Erythema Nodosum.</article-title>
            <source>Actas Dermosifiliogr</source>
            <year>2017</year>
            <season>Jul-Aug</season>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>591</fpage>
            <page-range>591-593</page-range>
            <pub-id pub-id-type="pmid">28262113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karaahmet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akinci</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ayte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hamamci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coskun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yuksel</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Tremor as dose dependent side-effect of azathioprine in remission patient with ileal Crohn's disease.</article-title>
            <source>J Crohns Colitis</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>9</issue>
            <fpage>e404</fpage>
            <pub-id pub-id-type="pmid">23623283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuggle</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Bragoli</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mahto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Glover</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Kinsler</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>72</volume>
            <issue>1</issue>
            <fpage>108</fpage>
            <page-range>108-14</page-range>
            <pub-id pub-id-type="pmid">25440430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trivedi</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Pitchumoni</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced pancreatitis: an update.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>8</issue>
            <fpage>709</fpage>
            <page-range>709-16</page-range>
            <pub-id pub-id-type="pmid">16082282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Geenen</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Stassen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Linskens</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Bruno</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Stegeman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>van Bodegraven</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Azathioprine or mercaptopurine-induced acute pancreatitis is not a disease-specific phenomenon.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>1322</fpage>
            <page-range>1322-9</page-range>
            <pub-id pub-id-type="pmid">20222913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shaffrali</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>An unusual side effect of azathioprine.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>929</fpage>
            <page-range>929-30</page-range>
            <pub-id pub-id-type="pmid">25810100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Woude</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Ardizzone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bengtson</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Fiorino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Katsanos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kolacek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Juillerat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mulders</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Selinger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sebastian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sturm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zelinkova</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Magro</surname>
                <given-names>F</given-names>
              </name>
              <collab>European Crohn&#x02019;s and Colitis Organization</collab>
            </person-group>
            <article-title>The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease.</article-title>
            <source>J Crohns Colitis</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>107</fpage>
            <page-range>107-24</page-range>
            <pub-id pub-id-type="pmid">25602023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Provan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stasi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Newland</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Blanchette</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Bolton-Maggs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Cines</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Gernsheimer</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Godeau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grainger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Imbach</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McMillan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tarantino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuter</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>International consensus report on the investigation and management of primary immune thrombocytopenia.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Jan</month>
            <day>14</day>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>168</fpage>
            <page-range>168-86</page-range>
            <pub-id pub-id-type="pmid">19846889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Immunosuppressive drug use in pregnancy.</article-title>
            <source>Autoimmunity</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-6</page-range>
            <pub-id pub-id-type="pmid">12765471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Korman</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Elmets</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Van Voorhees</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Beutner</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Bhushan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>451</fpage>
            <page-range>451-85</page-range>
            <pub-id pub-id-type="pmid">19493586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jack</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Koopman</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Hulley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nicolle</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>A Review of Azathioprine-Associated Hepatotoxicity and Myelosuppression in Myasthenia Gravis.</article-title>
            <source>J Clin Neuromuscul Dis</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-20</page-range>
            <pub-id pub-id-type="pmid">27552384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18065.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregoriano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ceschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rauber-L&#x000fc;thy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kupferschmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Banner</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Kr&#x000e4;henb&#x000fc;hl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taegtmeyer</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Acute thiopurine overdose: analysis of reports to a National Poison Centre 1995-2013.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>e86390</fpage>
            <pub-id pub-id-type="pmid">24489721</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
